| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PPP1R1C |
| Uniprot No | Q8WVI7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-109aa |
| 氨基酸序列 | MEPNSPKKIQ FAVPVFQSQI APEAAEQIRK RRPTPASLVI LNEHNPPEID DKRGPNTQGE LQNASPKQRK QSVYTPPTIK GVKHLKGQNE SAFPEEEEGT NEREEQRDH |
| 预测分子量 | 12,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PPP1R1C重组蛋白的模拟参考文献示例(文献内容为虚构演示)：
1. **"PPP1R1C重组蛋白在乳腺癌中的功能研究"**
*作者：Smith A, et al.*
摘要：本研究通过重组PPP1R1C蛋白发现其可显著增强乳腺癌细胞的增殖和迁移能力，机制可能与抑制蛋白磷酸酶1(PP1)活性并激活PI3K/AKT通路相关。
2. **"PPP1R1C重组蛋白的晶体结构解析及其调控机制"**
*作者：Zhang L, et al.*
摘要：首次报道PPP1R1C重组蛋白的晶体结构，揭示其通过N端结构域与PP1催化亚基特异性结合，调控下游靶标去磷酸化过程的结构基础。
3. **"PPP1R1C重组蛋白在神经突触可塑性中的作用"**
*作者：Tanaka K, et al.*
摘要：利用重组PPP1R1C蛋白进行体外实验，证明其通过cAMP/PKA信号通路调节突触后受体磷酸化水平，影响海马神经元的长时程增强(LTP)效应。
---
注：以上为模拟内容，实际文献需通过PubMed、Web of Science等数据库检索关键词(如"PPP1R1C recombinant" "protein phosphatase 1 regulatory subunit")。该蛋白的研究方向多集中于癌症、神经信号调控及代谢疾病领域。
PPP1R1C (Protein Phosphatase 1 Regulatory Inhibitor Subunit 1C) is a regulatory subunit of protein phosphatase 1 (PP1), a serine/threonine phosphatase central to diverse cellular processes, including cell cycle regulation, metabolism, and signal transduction. As a member of the PPP1R1 family, PPP1R1C modulates PP1's activity and substrate specificity by directing its localization and interaction with target proteins. It is expressed in tissue-specific patterns, with notable presence in the brain, suggesting roles in neuronal signaling and synaptic plasticity. Dysregulation of PP1 activity, influenced by regulators like PPP1R1C, has been implicated in neurological disorders, cancer, and metabolic diseases.
Recombinant PPP1R1C is engineered using expression systems (e.g., *E. coli* or mammalian cells) to produce purified protein for functional studies. Its recombinant form enables detailed analysis of PP1 regulatory mechanisms, such as phosphatase inhibition kinetics, structural interactions, and downstream signaling effects. Researchers employ it to explore how PPP1R1C fine-tunes PP1's role in dephosphorylating key substrates involved in apoptosis, DNA repair, or neurotransmitter release. Additionally, it serves as a tool for drug discovery, particularly in identifying molecules that modulate PP1 activity for therapeutic intervention in conditions linked to PP1 dysfunction. Studies also investigate PPP1R1C's potential as a biomarker or target in diseases like Alzheimer's or glioblastoma, where PP1 pathways are perturbed. Despite progress, challenges remain in understanding tissue-specific regulation and isoform diversity. Overall, recombinant PPP1R1C is pivotal in elucidating PP1's complex regulatory networks and their implications in health and disease.
×
